CELG - abraxane data in pancreatic cancer was good but not great, more importantly, not as good as hoped for. I am back in CELG 3/16/13 90.00 puts at 1.45. Looking for a retrace here after this run. The chart looks like it is rolling over. Needs to break SMA10 of 97.58. Indicators screaming oversold.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.